Core Viewpoint - The company, Kehua Bio-engineering, disclosed its construction in progress balance as of June 30, 2025, amounting to 1,640,045.17 yuan, which includes renovation and miscellaneous projects [1]. Group 1 - The company responded to investor inquiries on its interactive platform regarding its financial status [1]. - The balance of construction in progress is detailed in the company's semi-annual report for 2025 [1].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 新发突发与重大传染病防控 国家科技重大专项 "乙肝病毒多场景多元快速检测技术研发与应用"（项目编号： 2025ZD01906800 ） 项目启动会在北京医院召开 。项目相关领导、项目学术委员会专家、项目组成员等共同参与此次会议，围绕项目的技术路线、创新点与实施计 划等展开讨论。 新发突发与重大传染病防控国家科技重大专项遵循《"健康中国2030"规划纲要》《"十四五"国民健康规划》，旨在聚焦传染病防控领域的关 键技术难题，提升国家传染病防控能力。此次开展的项目由 北京医院（国家卫生健康委临床检验中心）王露楠教授担任项目负责人 ，联合四 川大学华西医院、南方医科大学南方医院、天隆科技等多家国内顶尖科研机构、临床医院及产业单位协同攻关。天隆科技凭借在传染病检测领 域的技术积淀与行业影响力，成为该项目中子课题 "高敏便携式HBV DNA即时检测关键技术研究与系统研制" 的牵头承担单位，全力推进乙 肝快速检测相关技术的研发与落地应用。 我 国 乙 肝 病 毒 （ HBV ） 感 染 人 群 基 ...

Core Insights - In 2025, a total of 10 flow cytometers received NMPA certification, with 9 being domestic brands, indicating a trend towards high-end, intelligent, and multi-parameter technology that supports clinical precision medicine [1][30]. Group 1: Industry Overview - Flow cytometry, developed in the 1970s, has evolved from basic research to clinical applications in disease diagnosis and treatment monitoring, with the first flow cytometer introduced in China in the early 1980s [2]. - Flow cytometers can measure cell size, internal particle characteristics, and detect surface and cytoplasmic antigens, as well as DNA and RNA content, allowing for rapid analysis of large cell populations [2]. Group 2: Certification and Product Highlights - In 2025, 10 flow cytometers were approved, including 9 domestic brands and 1 imported brand, with notable models such as Cl inStel lar AX from Chenglang Bio, which received certification in December [3][6]. - The Cl inStel lar AX is a high-end spectral flow cytometer that breaks the monopoly of imported brands in the high-end clinical field, providing cost-effective solutions for domestic medical institutions [6][30]. - The BioCy teX from Zhongsheng Medical is the first domestic 4-laser 21-color flow cytometer, marking a significant breakthrough in high-end flow cytometry capabilities [15][30]. Group 3: Technological Advancements - Prism Tech has achieved breakthroughs in PMT and APD detector technologies, creating a dual-platform system that enhances the technical breadth and application depth of domestic flow cytometers [7][30]. - Automation and intelligence upgrades are evident in devices like the Khroma series from Meiruite and EasyCell Plus from Weigong Technology, which feature high-throughput automatic sample loading systems [10][19][30]. Group 4: Market Trends and Future Outlook - The rapid increase in domestic brand certifications indicates a shift towards domestic alternatives and internationalization, with Zhongsheng Medical's BioCy te gaining registration in Indonesia, marking the beginning of overseas expansion for domestic manufacturers [31]. - The flow cytometry market is moving towards automation, intelligence, and multi-dimensional development, expanding applications from hematology to oncology, cell therapy, and infectious immunity [31].

Group 1 - The core point of the article is that the company, CaiNa Technology Co., Ltd., has received a patent for a "backflow prevention blood collection needle" from the National Intellectual Property Administration of China [1] - The patent was granted to Jiangsu CaiNa Medical Technology Co., Ltd., a wholly-owned subsidiary of CaiNa Technology [1] Group 2 - The article also highlights the trend of young executives, specifically those born in the 2000s, taking on significant roles in A-share companies, which poses a challenge to meet investor expectations [1] - A specific example mentioned is a 26-year-old who has recently returned from studying at a prestigious American university and has assumed the roles of chairman and general manager [1]

Group 1 - The core issue revolves around misleading statements made by the company regarding its involvement in the brain-computer interface sector, leading to a regulatory investigation by the China Securities Regulatory Commission (CSRC) [1][4] - The company announced a strategic cooperation framework in early January, claiming its partner was engaged in both invasive and non-invasive technologies, which resulted in a 6.52% increase in stock price and a nearly threefold increase in trading volume on the announcement day [1][4] - Following regulatory scrutiny, the company issued a supplementary announcement clarifying that the partner had no invasive technology and was only in the early stages of non-invasive technology development, revealing significant discrepancies in their disclosures [2][4] Group 2 - Prior to the CSRC's investigation, the Shanghai Stock Exchange had already issued a regulatory warning on January 7, highlighting inaccuracies and incompleteness in the company's disclosures [3][5] - The exchange emphasized the need for the company to provide adequate risk warnings regarding the feasibility and uncertainties of the partnership, as the brain-computer interface is a highly scrutinized market area [5] - The company has been ordered to submit a comprehensive rectification report, with all directors and executives required to confirm their signatures, and to conduct a thorough internal compliance review [5]

Core Viewpoint - North Chip Life (688712.SH) experienced a significant decline in stock price, closing at 44.83 yuan, down 5.74%, marking a new low since its listing on February 5, 2023 [1] Group 1: Company Overview - North Chip Life was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2023, with an issuance of 57 million shares, representing 13.67% of the total share capital post-issuance [1] - The initial offering price was set at 17.52 yuan per share [1] Group 2: Fundraising Details - The total amount raised from the issuance was 998.64 million yuan, with a net amount of 898.89 million yuan after deducting issuance costs [1] - The net fundraising amount was 53.32 million yuan less than the original plan of 952.21 million yuan [1] - The total issuance costs amounted to 99.75 million yuan, excluding VAT, with underwriting and sponsorship fees of 73.00 million yuan [1] Group 3: Future Plans - The funds raised are intended for the construction of an interventional medical device industrialization base, research and development projects for interventional medical devices, and to supplement working capital [1]

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug sector, including BeiGene, WuXi Biologics, Innovent Biologics, and others, while assigning a "Neutral" rating to China National Pharmaceutical Group [1]. Core Insights - The Hang Seng Healthcare Index fell by 1.4% during the week of February 2-6, 2026, outperforming the Hang Seng Index by 1.6 percentage points. Year-to-date, the Hang Seng Healthcare Index has risen by 7.0%, surpassing the Hang Seng Index by 3.4 percentage points. The report indicates a recovery in market sentiment towards the end of the week, with a focus on companies with strong earnings visibility in internet healthcare and CXO/research services [4][39]. - Notable performances among Hong Kong-listed healthcare stocks included Henlius (+11%), Ascletis Pharma (+10%), and others, while TransThera Biosciences (-15%) and MicroPort MedBot (-11%) showed weaker performance [40]. - The report highlights significant licensing deals in the biotech sector, which are expected to enhance market attention and recovery [4][39]. Summary by Sections Market Performance - The Hang Seng Healthcare Index's performance was better than the broader market, with various sub-sectors showing mixed results. Medical Services (+1.9%) and CXO/Research Services (+1.7%) performed well, while Internet Healthcare (-6.1%) and Biotech (-2.0%) lagged [4][26]. Company Highlights - Innovent Biologics is projected to achieve a total product revenue of approximately RMB 11.9 billion in 2025, reflecting a year-on-year increase of 45% [42]. - Merck reported a revenue of $65 billion for 2025, with a net profit of $18.3 billion, both meeting prior guidance [43]. - Eli Lilly's revenue for 2025 reached $65.2 billion, a 45% increase, with projections for 2026 between $80-83 billion [43][21]. Strategic Collaborations - SGB Biotech entered a global licensing agreement with Genentech for an RNAi drug, receiving an upfront payment of $200 million and potential milestone payments totaling $1.5 billion [42]. - Innovent Biologics and Eli Lilly announced a global strategic collaboration to advance innovative drugs in oncology and immunology [24].

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for customized porous tantalum dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company went public on December 30, 2021, and primarily engages in the research, production, and sales of implantable orthopedic medical devices [7]. - The main products include joint prosthetics and spinal implant products, covering four major human joints: hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [8]. Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is involved in various concept sectors including dental medical, robotics, and innovative enterprises [8]. Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.9585 million shares, and new entrants such as China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A [9].

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

IPO Pipeline Overview - As of February 8, there are 318 companies in the IPO pipeline, with 20 on the Shanghai Main Board, 41 on the Sci-Tech Innovation Board, 18 on the Shenzhen Main Board, 37 on the Growth Enterprise Market, and 202 on the Beijing Stock Exchange [2] - The total number of companies at various stages includes 8 accepted, 227 under inquiry, 16 approved, 46 suspended, and 21 submitted for registration [3] Newly Listed Companies - Two companies were newly listed between February 2 and February 8: - Shimen Supply Chain Management Co., Ltd. listed on February 3 on the Shenzhen Main Board with stock code 001220, closing at 57.73 yuan per share, a rise of 106.18%, with a trading volume of 1.093 billion yuan and a turnover rate of 76.68% [5] - Shenzhen Beixin Life Technology Co., Ltd. listed on February 5 on the Sci-Tech Innovation Board with stock code 688712, closing at 49.64 yuan per share, a rise of 183.33%, with a trading volume of 1.409 billion yuan and a turnover rate of 75.88% [7] New Counseling Records - A total of 14 companies received new counseling records from February 2 to February 8, including: - Tianjin Sanying Precision Instrument Co., Ltd. focusing on high-end X-ray non-destructive testing equipment [9] - Tianyi Space Technology Co., Ltd. specializing in SAR satellite constellation operations [10] - Guangdong Shenpeng Technology Co., Ltd. engaged in the development and production of brushless DC electronic water pumps [10] Approval Status - Three companies successfully passed the review process from February 2 to February 8: - Anhui Xinfeng New Energy Technology Co., Ltd. focusing on thermal management components for new energy vehicles [14] - Guangdong Huahui Intelligent Equipment Co., Ltd. specializing in high-end intelligent equipment [14] - Shandong Chunguang Technology Group Co., Ltd. aiming to become a world-class manufacturer of magnetic materials [15] Registration Approval - Two companies received registration approval during the same period: - Wuhu Aiteke Automotive Electronics Co., Ltd. providing automotive electronic solutions [16] - Hangzhou Gaote Electronic Equipment Co., Ltd. focusing on battery management systems for the new energy sector [16] Termination of Review - Wuxi Jiangsong Technology Co., Ltd. withdrew its IPO application during the period, specializing in high-end intelligent equipment for photovoltaic cells [19]